Citius Pharmaceuticals, Inc. SEC filings CTXR
Citius Pharmaceuticals, Inc. has 638 filings in SEC EDGAR's recent list, going back to Nov 23, 2010. Its latest annual report, Form ARS, was filed on Feb 24, 2026 for the period ended Sep 30, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (other events). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Feb 13, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 10-Q | Quarterly report | Feb 14, 2025 | Dec 31, 2024 |
| 10-Q | Quarterly report | Aug 12, 2024 | Jun 30, 2024 |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| 10-Q | Quarterly report | Feb 14, 2024 | Dec 31, 2023 |
| 10-Q | Quarterly report | Aug 14, 2023 | Jun 30, 2023 |
| 10-Q | Quarterly report | May 12, 2023 | Mar 31, 2023 |
| 10-Q | Quarterly report | Feb 10, 2023 | Dec 31, 2022 |
| 10-Q | Quarterly report | Aug 11, 2022 | Jun 30, 2022 |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| 10-Q | Quarterly report | Feb 10, 2022 | Dec 31, 2021 |
| 10-Q | Quarterly report | Aug 12, 2021 | Jun 30, 2021 |
| 10-Q | Quarterly report | May 13, 2021 | Mar 31, 2021 |
| 10-Q | Quarterly report | Feb 11, 2021 | Dec 31, 2020 |
| 10-Q | Quarterly report | Aug 14, 2020 | Jun 30, 2020 |
| 10-Q | Quarterly report | May 14, 2020 | Mar 31, 2020 |
| 10-Q | Quarterly report | Feb 13, 2020 | Dec 31, 2019 |
| 10-Q | Quarterly report | Aug 14, 2019 | Jun 30, 2019 |
| 10-Q | Quarterly report | May 15, 2019 | Mar 31, 2019 |
| 10-Q | Quarterly report | Feb 14, 2019 | Dec 31, 2018 |
| 10-Q | Quarterly report | Aug 14, 2018 | Jun 30, 2018 |
| 10-Q | Quarterly report | May 11, 2018 | Mar 31, 2018 |
| 10-Q | Quarterly report | Feb 14, 2018 | Dec 31, 2017 |
| 10-Q | Quarterly report | Aug 14, 2017 | Jun 30, 2017 |
| 10-Q | Quarterly report | May 15, 2017 | Mar 31, 2017 |
| 10-Q | Quarterly report | Feb 14, 2017 | Dec 31, 2016 |
| 10-Q | Quarterly report | Aug 15, 2016 | Jun 30, 2016 |
| 10-Q | Quarterly report | May 20, 2016 | Mar 31, 2016 |
| 10-Q | Quarterly report | Feb 12, 2016 | Dec 31, 2015 |
| 10-Q | Quarterly report | Aug 13, 2015 | Jun 30, 2015 |
| 10-Q | Quarterly report | May 13, 2015 | Mar 31, 2015 |
| 10-Q | Quarterly report | Feb 17, 2015 | Dec 31, 2014 |
| 10-Q | Quarterly report | Aug 14, 2014 | Jun 30, 2014 |
| 10-Q | Quarterly report | May 15, 2014 | Mar 31, 2014 |
| 10-Q | Quarterly report | Feb 19, 2014 | Dec 31, 2013 |
| 10-Q | Quarterly report | Sep 18, 2013 | Jun 30, 2013 |
| 10-Q | Quarterly report | May 13, 2013 | Mar 31, 2013 |
| 10-Q | Quarterly report | Feb 8, 2013 | Dec 31, 2012 |
| 10-Q | Quarterly report | Aug 17, 2012 | Jun 30, 2012 |
| 10-Q | Quarterly report | May 11, 2012 | Mar 31, 2012 |
| 10-Q | Quarterly report | Feb 14, 2012 | Dec 31, 2011 |
| 10-Q | Quarterly report | Aug 26, 2011 | Jun 30, 2011 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CTXR (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- NV
- Headquarters
- Cranford, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1506251
- Former names
- Trail One, Inc. (until Sep 18, 2014); TrailOne, Inc. (until Jan 21, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.